Medical experts are warning that injections marketed for weight loss are specifically formulated as anti-obesity medications and are not intended for minor weight reduction or cosmetic use. This distinction is critical, as the misuse of these potent pharmaceuticals—often popularized on social media as “miracle” products—carries significant risks to patient health.
The Dangers of Non-Clinical Use
According to internal medicine specialist Anastasia Eftychidou, who spoke with Ertnews, the primary concern lies in the improper use of these drugs by individuals seeking to lose small amounts of weight, such as “2–3 kilograms” for aesthetic reasons.
Dr. Eftychidou emphasizes that these medications are designed exclusively for patients diagnosed with obesity. When used without medical oversight, diet, and exercise, the weight lost is often lean muscle mass rather than fat. This physiological outcome makes it increasingly difficult to maintain the weight loss later, potentially trapping the user in a cycle of repeated, unnecessary pharmacological intervention.
Clinical Risks and Gastrointestinal Side Effects
The medical community highlights that side effects are a common reality for those using these agents. Gastrointestinal issues are the most frequent, including nausea, vomiting, and abdominal pain. Experts argue that for individuals who are not clinically obese, the risk of these adverse events is unjustified, particularly given that safer, non-pharmaceutical methods exist for minor weight management.
The study, which evaluated 262 trials involving 99,791 participants, found that drugs yielding the most significant weight loss often correlate with higher rates of treatment discontinuation due to adverse reactions.
Findings from Comparative Research
The analysis of 19 different weight-loss medications revealed that while some molecules are highly effective at reducing body mass, they come with substantial trade-offs.
* Weight Loss and Muscle Impact: Tirzepatide, for instance, showed a significant reduction in fat mass (-25.7%), but also resulted in an 8.3% reduction in lean muscle mass. * Treatment Discontinuation: Data indicates a higher risk of stopping treatment due to adverse effects with drugs such as orforglipron, naltrexone-bupropion, liraglutide, phentermine-topiramate, cagrilintide-semaglutide, and oral semaglutide. * Specific Adverse Events: Gastrointestinal events were notably higher with the use of naltrexone-bupropion, oral semaglutide, orforglipron, and tirzepatide. Additionally, an increased risk of fatigue was associated with naltrexone-bupropion, orforglipron, and cagrilintide-semaglutide.
The researchers also noted that for many of these products, the improvement in overall quality of life is minimal. While subcutaneous semaglutide and tirzepatide showed potential in reducing the risk of heart failure, and subcutaneous semaglutide was the only medication associated with a reduction in all-cause mortality, these clinical outcomes remain specific to the treatment of obesity rather than general weight loss.
Experts conclude that the ease of access to these medications remains a significant public health concern. Because all such drugs carry specific indications and contraindications, they must be evaluated by a physician to avoid the risks associated with self-administration.
Sources: Ertnews.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.